Literature DB >> 27388253

Copy number and expression analysis of FOSL1, GSTP1, NTSR1, FADD and CCND1 genes in primary breast tumors with axillary lymph node metastasis.

Cíntia C F Callegari1, Iglenir J Cavalli1, Rubens S Lima2, Tayana S Jucoski1, Clarissa Torresan1, Cicero A Urban3, Flavia Kuroda2, Karina F Anselmi2, Luciane R Cavalli4, Enilze M S F Ribeiro1.   

Abstract

In breast cancer, lymph node (LN) metastasis is one of the strongest prognostic factors at diagnosis. Therefore the identification of molecular markers with metastatic potential that promote the development of LN metastasis is of critical clinical relevance. In this study, we evaluated the copy number status of the FOSL1, GSTP1, NTSR1, FADD and CCND1 genes by TaqMan assays in 137 breast cancer patients, 84 with LN metastasis (LN+) and 53 with no LN metastasis (LN-). The copy number data for four of these genes (FOSL1, GSTP1, FADD and CCND1) were integrated with their mRNA expression levels in 31 patients. In both groups of patients, gains were the most frequent copy number alteration (CNA) observed, involving mainly the CCND1, NTSR1 and FADD genes; mRNA overexpression was more commonly observed for the CCND1 and FADD genes. For the FADD gene in the LN+ group, gene expression was shown to be dependent on CNAs; for the other genes no association was found. In conclusion, increase copy number and mRNA overexpression of FOSL1, GSTP1, FADD, NTSR1 and CCND1 genes are frequently observed in primary breast tumors, and except for the FADD gene, they occur independently and irrespectively of the patients' LN axillary metastatic status.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast cancer; DNA copy number; gene expression; lymph node; metastasis

Mesh:

Substances:

Year:  2016        PMID: 27388253     DOI: 10.1016/j.cancergen.2016.06.003

Source DB:  PubMed          Journal:  Cancer Genet


  7 in total

1.  Expression of neurotensin receptor-1 (NTS1) in primary breast tumors, cellular distribution, and association with clinical and biological factors.

Authors:  Clément Morgat; Véronique Brouste; Adrien Chastel; Valérie Vélasco; Gaétan Macgrogan; Elif Hindié
Journal:  Breast Cancer Res Treat       Date:  2021-10-01       Impact factor: 4.872

2.  Breast Cancer Patient-Derived Scaffolds Can Expose Unique Individual Cancer Progressing Properties of the Cancer Microenvironment Associated with Clinical Characteristics.

Authors:  Elena Garre; Anna Gustafsson; Maria Carmen Leiva; Joakim Håkansson; Anders Ståhlberg; Anikó Kovács; Göran Landberg
Journal:  Cancers (Basel)       Date:  2022-04-26       Impact factor: 6.575

3.  Gene-based comparative analysis of tools for estimating copy number alterations using whole-exome sequencing data.

Authors:  Hyung-Yong Kim; Jin-Woo Choi; Jeong-Yeon Lee; Gu Kong
Journal:  Oncotarget       Date:  2017-04-18

4.  Development of an autophagy-related gene prognostic signature in lung adenocarcinoma and lung squamous cell carcinoma.

Authors:  Jie Zhu; Min Wang; Daixing Hu
Journal:  PeerJ       Date:  2020-01-07       Impact factor: 2.984

5.  Clinical Impact of 11q13.3 Amplification on Immune Cell Infiltration and Prognosis in Breast Cancer.

Authors:  Renyu Zhou; Xiaoxi Zhu; Yulong Peng; Lijuan Zhong; Lilin Peng; Bo Yang; Yuhua Meng; Xuanzhao Chen; Yuanzhi Lu
Journal:  Int J Gen Med       Date:  2022-04-14

Review 6.  FADD in Cancer: Mechanisms of Altered Expression and Function, and Clinical Implications.

Authors:  José L Marín-Rubio; Laura Vela-Martín; José Fernández-Piqueras; María Villa-Morales
Journal:  Cancers (Basel)       Date:  2019-09-29       Impact factor: 6.639

7.  Integrative Analysis of the Doxorubicin-Associated LncRNA-mRNA Network Identifies Chemoresistance-Associated lnc-TRDMT1-5 as a Biomarker of Breast Cancer Progression.

Authors:  Qi Chen; Hui Yang; Xiaolan Zhu; Shangwan Xiong; Huamao Chi; Wenlin Xu
Journal:  Front Genet       Date:  2020-05-29       Impact factor: 4.599

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.